EP0493470A1 - Techniques d'analyse et reactifs servant a detecter les depots d'amyloide - Google Patents
Techniques d'analyse et reactifs servant a detecter les depots d'amyloideInfo
- Publication number
- EP0493470A1 EP0493470A1 EP90914284A EP90914284A EP0493470A1 EP 0493470 A1 EP0493470 A1 EP 0493470A1 EP 90914284 A EP90914284 A EP 90914284A EP 90914284 A EP90914284 A EP 90914284A EP 0493470 A1 EP0493470 A1 EP 0493470A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- amyloid
- preamyloid
- val
- protein
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 13
- 238000003556 assay Methods 0.000 title description 12
- 230000003941 amyloidogenesis Effects 0.000 title description 10
- 238000000034 method Methods 0.000 claims abstract description 37
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 22
- 208000037259 Amyloid Plaque Diseases 0.000 claims abstract description 18
- 230000001900 immune effect Effects 0.000 claims abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 59
- 102000004169 proteins and genes Human genes 0.000 claims description 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 25
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 24
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 19
- 241000700618 Vaccinia virus Species 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 206010002022 amyloidosis Diseases 0.000 claims description 10
- 238000003018 immunoassay Methods 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 238000004113 cell culture Methods 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 108010037850 glycylvaline Proteins 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- SICITCLFXRGKJW-IIZANFQQSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 SICITCLFXRGKJW-IIZANFQQSA-N 0.000 claims description 2
- KXEVYGKATAMXJJ-ACZMJKKPSA-N Ala-Glu-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O KXEVYGKATAMXJJ-ACZMJKKPSA-N 0.000 claims description 2
- IETUUAHKCHOQHP-KZVJFYERSA-N Ala-Thr-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)N)[C@@H](C)O)C(O)=O IETUUAHKCHOQHP-KZVJFYERSA-N 0.000 claims description 2
- OMSKGWFGWCQFBD-KZVJFYERSA-N Ala-Val-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OMSKGWFGWCQFBD-KZVJFYERSA-N 0.000 claims description 2
- NVCIXQYNWYTLDO-IHRRRGAJSA-N Arg-His-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCCN=C(N)N)N NVCIXQYNWYTLDO-IHRRRGAJSA-N 0.000 claims description 2
- UDSVWSUXKYXSTR-QWRGUYRKSA-N Asn-Gly-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O UDSVWSUXKYXSTR-QWRGUYRKSA-N 0.000 claims description 2
- NYGILGUOUOXGMJ-YUMQZZPRSA-N Asn-Lys-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O NYGILGUOUOXGMJ-YUMQZZPRSA-N 0.000 claims description 2
- XEDQMTWEYFBOIK-ACZMJKKPSA-N Asp-Ala-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O XEDQMTWEYFBOIK-ACZMJKKPSA-N 0.000 claims description 2
- KGHLGJAXYSVNJP-WHFBIAKZSA-N Asp-Ser-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O KGHLGJAXYSVNJP-WHFBIAKZSA-N 0.000 claims description 2
- LXAUHIRMWXQRKI-XHNCKOQMSA-N Glu-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N)C(=O)O LXAUHIRMWXQRKI-XHNCKOQMSA-N 0.000 claims description 2
- YSDLIYZLOTZZNP-UWVGGRQHSA-N Gly-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN YSDLIYZLOTZZNP-UWVGGRQHSA-N 0.000 claims description 2
- JIUYRPFQJJRSJB-QWRGUYRKSA-N His-His-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)NCC(O)=O)C1=CN=CN1 JIUYRPFQJJRSJB-QWRGUYRKSA-N 0.000 claims description 2
- KMSMNUFBNCHMII-IHRRRGAJSA-N Met-Leu-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN KMSMNUFBNCHMII-IHRRRGAJSA-N 0.000 claims description 2
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 claims description 2
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 claims description 2
- 108010065395 Neuropep-1 Proteins 0.000 claims description 2
- MQWISMJKHOUEMW-ULQDDVLXSA-N Phe-Arg-His Chemical compound C([C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=CC=C1 MQWISMJKHOUEMW-ULQDDVLXSA-N 0.000 claims description 2
- FRKBNXCFJBPJOL-GUBZILKMSA-N Pro-Glu-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O FRKBNXCFJBPJOL-GUBZILKMSA-N 0.000 claims description 2
- OCWWJBZQXGYQCA-DCAQKATOSA-N Ser-Lys-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O OCWWJBZQXGYQCA-DCAQKATOSA-N 0.000 claims description 2
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 claims description 2
- UNUZEBFXGWVAOP-DZKIICNBSA-N Tyr-Glu-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UNUZEBFXGWVAOP-DZKIICNBSA-N 0.000 claims description 2
- CWVHKVVKAQIJKY-ACRUOGEOSA-N Tyr-Lys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CC=C(C=C2)O)N CWVHKVVKAQIJKY-ACRUOGEOSA-N 0.000 claims description 2
- WQOHKVRQDLNDIL-YJRXYDGGSA-N Tyr-Thr-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O WQOHKVRQDLNDIL-YJRXYDGGSA-N 0.000 claims description 2
- ISERLACIZUGCDX-ZKWXMUAHSA-N Val-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N ISERLACIZUGCDX-ZKWXMUAHSA-N 0.000 claims description 2
- PIFJAFRUVWZRKR-QMMMGPOBSA-N Val-Gly-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O PIFJAFRUVWZRKR-QMMMGPOBSA-N 0.000 claims description 2
- LAYSXAOGWHKNED-XPUUQOCRSA-N Val-Gly-Ser Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LAYSXAOGWHKNED-XPUUQOCRSA-N 0.000 claims description 2
- NLNCNKIVJPEFBC-DLOVCJGASA-N Val-Val-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O NLNCNKIVJPEFBC-DLOVCJGASA-N 0.000 claims description 2
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 claims description 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 claims description 2
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 claims description 2
- 108010087823 glycyltyrosine Proteins 0.000 claims description 2
- 108010028295 histidylhistidine Proteins 0.000 claims description 2
- 108010054155 lysyllysine Proteins 0.000 claims description 2
- 108010073025 phenylalanylphenylalanine Proteins 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000007505 plaque formation Effects 0.000 claims 2
- 230000003698 anagen phase Effects 0.000 claims 1
- 238000006911 enzymatic reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 8
- 238000000338 in vitro Methods 0.000 abstract description 6
- 238000004458 analytical method Methods 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 77
- 235000018102 proteins Nutrition 0.000 description 36
- 150000001413 amino acids Chemical group 0.000 description 28
- 230000014509 gene expression Effects 0.000 description 28
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 25
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 25
- 239000013598 vector Substances 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 22
- 206010046865 Vaccinia virus infection Diseases 0.000 description 15
- 208000007089 vaccinia Diseases 0.000 description 15
- 101710132601 Capsid protein Proteins 0.000 description 11
- 241000700605 Viruses Species 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 239000002243 precursor Substances 0.000 description 10
- 108010085238 Actins Proteins 0.000 description 9
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 102000007469 Actins Human genes 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 6
- 239000012491 analyte Substances 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229960004452 methionine Drugs 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 102000001049 Amyloid Human genes 0.000 description 3
- 108010094108 Amyloid Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- -1 isocytochrome C Proteins 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000002241 neurite Anatomy 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 1
- 101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 101001035365 Arabidopsis thaliana Histone H2B.9 Proteins 0.000 description 1
- SONUFGRSSMFHFN-IMJSIDKUSA-N Asn-Ser Chemical group NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O SONUFGRSSMFHFN-IMJSIDKUSA-N 0.000 description 1
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
- 241000713842 Avian sarcoma virus Species 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 108700004676 Bence Jones Proteins 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000032838 Hereditary amyloidosis with primary renal involvement Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020497 Nucleopolyhedrovirus polyhedrin Proteins 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 238000002799 binding type assay Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- NNBFNNNWANBMTI-UHFFFAOYSA-M brilliant green Chemical compound OS([O-])(=O)=O.C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 NNBFNNNWANBMTI-UHFFFAOYSA-M 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000005137 deposition process Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 201000007891 familial visceral amyloidosis Diseases 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 108010077055 methylated bovine serum albumin Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 150000003378 silver Chemical class 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Definitions
- the present invention relates to assays and re ⁇ agents useful for the chemical intervention of amyloidosis in Alzheimer's disease.
- AD Alzheimer's disease
- NFT neurofibrillary tangles
- the major protein component of amyloid is an ⁇ 4 kilodalton (kd) protein, designated the beta-protein or A4 protein due to a partial beta pleated structure or its molecular weight, respectively.
- the A4 protein accumulates extracellularly, both in brain parenchyma and in the walls of blood vessels, generally as amyloid plaques which form aggregate fibril structures and are insoluble on SDS-polyacrylamide gels.
- the fibrils are generally identified as amyloid based on their green birefringence after staining with Congo red and their 40- to 90-A diameter.
- the second protein mentioned previously, ac ⁇ cumulates intracellularly in neurons of Alzheimer's brains (Castano and Frangione, (1988) Lab Invest 58:122-132) and forms tangles composed of structures resembling paired helical filaments (PHFs).
- PHFs paired helical filaments
- the primary structure and number of proteins comprising PHFs are unknown.
- PHF-containing neurites are found in the periphery of the plaque, whereas deposits of beta-amyloid protein form the central core of mature plaques, surrounded by degenerated neurites and glial cells.
- the present invention provides a method for determining the ability of a potential therapeutic agent to intervene in the amyloid deposition process associated with Alzheimer's disease in a cellular environment, which method utilizes a recombinantly produced amyloid substrate in a screening assay.
- the present invention also allows for the development and use of immunological reagents to detect the formation of preamyloid protein aggregation in the cell lines provided by the invention.
- a method of screening agents capable of intervention in Alzheimer's disease amyloidosis comprises: a) culturing a cell line capable of expressing a gene encoding beta-amyloid protein under conditions suit- able to produce the beta-amyloid protein as an insoluble, preamyloid aggregate; b) combining a known quantity of the agent to be tested to the cell culture; and c) monitoring the combination to determine whether preamyloid aggregate formation is reduced.
- preamyloid formation can be induced through infection of a cell line with a recombinant virus capable of expressing the beta-amyloid protein as an insoluble preamyloid aggregate.
- recombinant viruses carry expression vectors comprising DNA encoding the beta-amyloid protein.
- Immunoassay kits employing the reagents useful to screen potential amyloid intervening agents are also provided by the present invention.
- FIG. 1 is a schematic illustration of two amyloid expression constructs employing the vaccinia pUVl insertion vector.
- FIG 2. illustrates the results of immunoprecipitation of 35S-methionine labeled W:A99 infected CV-1 cell lysates using APCP antibodies.
- FIG 3. are fluorescent photomicrographs of infected CV-1 cells stained with APCP antibodies.
- FIG. 3A is a Mock control;
- FIG. 3B is a W:CONT control;
- FIG. 3C is the W:99 construct; and
- FIG. 3D is the W:42 construct.
- the magnification is 200x with a 0.4 second exposure time for each photo.
- FIG. 4 is a illustration of the modified beta- actin expression selection vector, pAX-neo, that was employed to express the beta-amyloid core constructs in mammalian cells. Detailed Description of the Preferred Embodiments
- the invention involves a method of screening agents capable of intervention in Alzheimer's disease amyloidosis.
- beta-amyloid core protein or "A4 protein” refers to an approximately 4 kd protein first identified by Glenner and Wong, (1984) Biochem Biophvs Res Comm 120:885, which is defined at the amino terminus by sequence analysis as a mixture of four peptides with slightly different amino termini, the amino termini of the three smaller peptides being completely encoded by that of the largest.
- beta-amyloid precursor protein refers to either the amyloid precursor protein of 695 amino acids (Kang et al., (1987) supra) or the 751 amino acid protein (Ponte et al., (1988) supra) containing within their sequence, the beta-amyloid core protein sequence defined above.
- the A4 core protein begins at amino acid 597 of the 695 amino acid protein and at amino acid 653 of the 751 amino acid sequence.
- preamyloid aggregation refers to a morphological description — first discovered by Tagliavini et al., (1988) Neurosci Lett 93:191-196 — of spherical, granular deposits which are considerably smaller than pre-plaques and plaques found at a high frequency in the brains of Alzheimer's victims. These deposits can be occasionally detected with silver stain but not with Congo red, a stain to which amyloid proteins demonstrate high binding affinity.
- insertion vector includes plasmids, cosmids or phages capable of mediating homologous recombination into a viral genome such that the DNA encoding the beta-amyloid protein is stably carried by the resulting recombinant virus.
- plasmids constructed from vaccinia virus DNA are employed.
- expression vector includes plasmids, cosmids or phages capable of synthesizing a protein encoded by the respective recombinant gene carried by said vector. Such vectors are independently replicated in or capable of integration into the chromosome of an appropri ⁇ ate host cell for expression of the amyloid protein.
- a cell has been "transformed” by exogenous or heterologous DNA when such DNA has been introduced inside the cell.
- the transforming DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell.
- the transforming DNA may be maintained on an episomal element such as a plasmid.
- the cell has been stably transformed when the cell is able to establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA.
- a "clone” is a population of cells derived from a single cell or common ancestor by mitosis.
- a "cell line” is a clone of a cell that is capable of stable growth in vitro for many generations.
- Beta-Amyloid Coding Sequences The beta-amyloid genes may be synthetic or natural, or combinations thereof.
- the gene encoding the natural 751 amino acid precursor protein is described in PCT WO88/03951, published 2 June 1988 and assigned to the same assignee of the present application, and the expres- sion of the protein in mammalian cells is provided in
- Example 4 therein. The relevant portions of this publica ⁇ tion are specifically incorporated herein by reference.
- the genes encode the A42 core protein or an amyloid protein, A99, which comprises the A42 core protein and the cytoplasmic domain.
- A99 which comprises the A42 core protein and the cytoplasmic domain.
- This latter protein consists of the 42 residue core protein and 57 amino acids of the cytoplasmic domain of the 751 precursor protein.
- the sequence of A99 is as follows:
- genes are provided for expression of the desired protein using recombinant DNA expression vectors.
- these genes may be natural, synthetic or combinations thereof.
- it may be desirable to modify the natural amyloid nucleic acid sequence. For example, it will often be preferred to use codons which are preferentially recognized by the desired host.
- it may be desirable to further alter the nucleotide sequence, either synthetic or natural, to create or remove restriction sites to, for example, enhance insertion of the gene sequence into convenient expression vectors or to substitute one or more amino acids in the resulting polypeptide to increase stability.
- a general method for site-specific mutagenesis is described in Noren et al., (1989) Science 244:182-188.
- Peptides of this precursor protein are also provided herein for the generation of specific immunological re- agents and may also be synthetic or natural.
- Synthetic oligonucleotides are prepared by either the phosphotriester method as described by Edge et al., (1981) Nature 292:756 and Duckworth et al., (1981) Nuc Acids Res ⁇ :1691 or the phosphoramidite method as described by Beaucage and Caruthers, (1981) Tet Lett 22:1859 and Matteucci and Caruthers, (1981) J Am Chem Soc 103:3185, and can be prepared using commercially available automated oligonucleotide synthesizers.
- the coding sequences for the amyloid proteins can be inserted into vaccinia virus plasmid insertion vec ⁇ tors for the purpose of generating recombinant vaccinia viruses using the methods described in Moss et al., (1983) Methods in Gene Amplification, Vol. 3, Elsevier-North Hol ⁇ land, p. 202-213; and in Moss et al., (1984) J Virol 4jJ:857-864.
- the amyloid-vaccinia recombinants can then be used for (1) expression of the respective amyloid protein and analysis of preamyloid formation, and (2) production of amyloid antibodies.
- the two vaccinia virus insertion vectors pSCll (Chakrabarti et al., (1985) Mol Cell Biol 5:3403-3409 and pUVl (Falkner et al., (1987) Nuc Acids Res 15:7192) were used for the expression of the amyloid proteins and generation of amyloid-vaccinia recombinants. Both vectors are of the co-insertion variety and each contains two vaccinia virus promoters. One promoter (PI) is used to drive the expression of a selectable marker gene (in this case, beta-galactosidase) while the other promoter (P2) is used to drive expression of the heterologous amyloid DNA insert.
- PI promoter
- P2 is used to drive expression of the heterologous amyloid DNA insert.
- the pSCll vector utilizes a vaccinia early-late promoter (P7.5) to drive heterologous gene expression and has a single S al cloning site.
- the pUVl vector utilizes a vaccinia late promoter (Pll) to drive heterologous gene expression and is designed for the expression of fusion proteins behind the ATG of the Pll late gene. In all cases, amyloid-pUVl constructs were made using the most 5' (after the ATG) cloning site (EcoRI) in order to avoid introduction of additional amino terminal amino acids into the native amyloid protein sequence.
- procaryotic and eucaryotic systems may be used to express the amyloid genes described herein.
- Procaryotes most frequently are represented by various strains of E. coli; however, other microbial strains may also be used.
- Plasmid vectors which contain replication sites, selectable markers and control sequences derived from a species compatible with the host are used; for example, E. coli is typically transformed using derivatives of pBR322, a plasmid derived from an E. coli species by Bolivar et al. , (1977) Gene 2:95.
- pBR322 contains genes for ampicillin and tetracycline resistance, and thus provides multiple selectable markers which can be either retained or destroyed in constructing the desired vector.
- Commonly used procaryotic control sequences which are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences, include such commonly used promoters as the beta-lactamase (penicillinase) and lactose (lac) promoter systems (Chang et al., (1977) Nature 198:1056), the tryptophan (trp) promoter system (Goeddel et al. , (1980) Nucleic Acids Res 8:4057), the lambda-derived P-. promoter (Shimatake et al. , (1981)
- eucaryotic microbes such as yeast
- yeast may also be used as hosts.
- Laboratory strains of Saccharomyces cerevisiae, Baker's yeast are most used although a number of other strains or species are commonly available.
- Vectors employing, for example, the 2 micron origin of replication of Broach, (1983) Meth Enz 101:307, or other yeast compatible origins of replica- tion (see, for example, Stinchcomb et al., (1979) Nature 282:39; Tschumper et al., (1980) Gene 10:157 and Clarke et al., (1983) Meth Enz 101:300) may be used.
- Control sequences for yeast vectors include promoters for the synthesis of glycolytic enzymes (Hess et al. , (1968) J Adv Enzyme Reg 7:149; Holland et al. , (1978) Biochemistry
- promoters known in the art include the promoter for 3-phosphoglycerate kinase (Hitzeman et al., (1980) J Biol Chem 255:2073).
- Other promoters which have the additional advantage of transcription controlled by growth conditions and/or genetic background are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, the alpha factor system and enzymes responsible for maltose and galactose utilization. It is also believed terminator sequences are desirable at the 3' end of the coding sequences. Such terminators are found in the 3' untranslated region fol ⁇ lowing the coding sequences in yeast-derived genes.
- eucaryotic host cell cultures derived from multicellular organisms. See, for example, Axel et al. , U.S. Patent No. 4,399,216. These systems have the additional advantage of the ability to splice out introns and thus can be used directly to express genomic ragments.
- Useful host cell lines include VERO, HeLa, baby hamster kidney (BHK), CV-1, COS, MDCK, NIH 3T3, L, and Chinese hamster ovary (CHO) cells. Expression vectors for such cells ordinarily include promoters and control sequences compatible with mammalian cells such as, for example, the commonly used early and late promoters from Simian Virus 40 (SV40) (Fiers et al., (1978) Nature
- viral promoters such as those derived from polyoma, herpes virus, Adenovirus 2, bovine papilloma virus, or avian sarcoma viruses.
- the controllable promoter, hMTII Kerin et al., (1987) Nature 299:797-802
- hMTII Kerin et al., (1987) Nature 299:797-802
- Insect expression systems may also be employed to express the amyloid genes.
- the baculovirus polyhedrin gene has been employed for high- level expression of heterologous proteins (Smith et al., (1983) Mol Cell Biol 3(12) :2156-2165; Summers et al., "Genetic Engineering of the Genome of the Autographa Californica Nuclear Polyhedrosis Virus", Banbury Report: Genetically Altered Viruses in the Environment, 22:319- 339, Cold Spring Harbor Laboratory, 1985).
- the amyloid DNA clones expressed in vaccinia can also be used to generate stably transfected cell lines expressing the amyloid proteins.
- these cell lines are generated by first constructing one of two expression plasmids.
- the selectable marker is provided by a G418 neomycin expres ⁇ sion cassette (neo) consisting of the SV40 early promoter, the bacterial kanamycin-resistance gene also containing its own promoter, the SV40 intervening sequence, and the SV40 polyadenylation site from the early region.
- the amyloid DNA cloning site is flanked at the 5' end by the human metallothionein gene promoter, pMtlla, modified with an SV40 enhancer, and at the 3' end by the SV40 polyadenylation site from the early region.
- the amyloid DNA cloning site is flanked at the 5' end by a beta-actin promoter, and at the 3' end by a sequence encoding a use ⁇ ful polyadenylation site, such as that of the SV40 early region or the beta-actin gene.
- Each of the vectors described above can be transformed into a mammalian cell line such as, but not limited to, those described in the following examples by either calcium phosphate-DNA coprecipitation or electro- poration.
- the cells are subjected to 1 mg/ml G418 to provide pools of G418-resistant colonies.
- Suc ⁇ cessful transformants also having a stable inheritance of the DNA contained in the expression construct, are then plated at low density for purification of clonal isolates. Clonal isolates are then analyzed for maximum production of the amyloid protein of interest and high-producing clones are expanded to serve as stock.
- the amyloid protein may need to be conjugated to a carrier protein such as bovine serum albumin or keyhole limpet hemacyanin using a chemical process which employs carbodiimide, glutaraldehyde, or other cross-linking agents.
- a carrier protein such as bovine serum albumin or keyhole limpet hemacyanin
- the protein may be administered without being conjugated to a carrier protein.
- Vaccinia virus re ⁇ combinants which are expressing amyloid proteins may also be used to prepare antibodies. The vaccinia virus re ⁇ combinants are injected into an animal and then the animal is boosted several weeks after the initial immunization. Ten days to two weeks later the animals are bled and antiserum is collected and analyzed for titer.
- Monoclonal antibodies are commonly prepared by fusing, under appropriate conditions, B-lymphocytes of an animal which is making polyclonal antibodies with an im ⁇ mortalizing myeloma cell line.
- the B-lymphocytes can be spleen cells or peripheral blood lymphocytes.
- Techniques for fusion are also well known in the art, and in general, involve mixing the cells with a fusing agent such as poly ⁇ ethylene glycol.
- Successful hybrid ⁇ ma formation is as ⁇ sessed and selected by standard procedures such as, for example, HAT medium. From among successful hybridomas, those secreting the desired antibody are screened by as ⁇ saying the culture medium for their presence.
- Standard immunological techniques such as ELISA (enzyme-linked immun ⁇ assay) , RIA (radioimmunoassay) , IFA (immunofluorescence assay) and Western blot analysis, which are well known in the art, can be employed for diagnostic screening for amyloid expression.
- ELISA enzyme-linked immun ⁇ assay
- RIA radioimmunoassay
- IFA immunofluorescence assay
- Western blot analysis which are well known in the art, can be employed for diagnostic screening for amyloid expression.
- One typical arrangement utilizes competition, between labeled antigen (e.g. amyloid protein) and the analyte, for the antibody, followed by physical separation of bound and unbound fractions.
- labeled antigen e.g. amyloid protein
- Analyte competes for the binding of the labeled antigen; hence more label will remain in the unbound fraction when larger amounts of analyte are present.
- this competitive-binding type assay the sample is incubated with a known titer of labeled amyloid protein and amyloid protein antibody.
- Antibody-protein complex is then separated from uncomplexed reagents using known techniques and the amount of label in the co plexed material is measured, e.g.
- the amount of amyloid protein in the sample is determined by comparing the measured amount of label with a standard curve.
- the present assay provides one of the first steps in addressing the question whether preamyloid corti- cal deposits herald organic dementia.
- Down's syndrome is the one known disease closely related to the proposed etiology of AD.
- NFTs congophilic angiopathy
- senile plaques As reported in Giacione et al.
- the expression of the amyloid protein is initiated by culturing the transformed cell line under conditions which are suitable for cell growth and expression of the amyloid protein.
- high level expression of the protein is preferred.
- a CHO cell line transformed with a beta-actin vector comprising the DNA encoding the A42 or A99 amyloid protein is grown in a mammalian culture medium such as, for example, a 1:1 mixture of F12 medium and DME medium with 10% fetal calf serum for 5-72 hr at 37°C.
- Transfected viral monolayers are selected and plaque purified, and stocks of amyloid-vaccinia recombinant viruses are prepared.
- preamyloid aggregates can be monitored by standard immunocytochemical methods using, for example, beta-amyloid primary antibodies which are detected using a secondary, labeled anti-antibody. If one is interested in testing whether the compound of interest can inhibit preamyloid formation, the compound is introduced to the culture medium before monitoring for preamyloid aggregation. Alternatively, the compound is introduced to the culture medium after preamyloid forma ⁇ tion has been established and this reaction mixture is monitored to see whether the compound induces amyloid resorption.
- Potential therapeutic compounds for use in the present invention include, for example, amyloid-fibril denaturing agents such as dimethyl sulfoxide, and cytotoxic agents such as colchicine and chlorambucil.
- amyloid-fibril denaturing agents such as dimethyl sulfoxide
- cytotoxic agents such as colchicine and chlorambucil.
- the efficacy of these agents may be monitored through observa ⁇ tion of reduced antibody binding to the amyloid deposit. Reduction in such binding is indicative of reduced preamyloid deposition.
- preamyloid formation in the host cell may trigger other cellular events which could be employed as markers unrelated to the etiology of Alzheimer's disease, but correlative with the presence of preamyloid deposits.
- an increase in the level of certain enzymes, specifically proteases may be measured in lieu of the preamyloid deposition.
- an increase in the concentration levels of these enzymes is observed when cultured cells are subjected to stress.
- kits suitable for the above diagnostic or screening methods contain the appropriate reagents and are constructed by packaging the appropriate materials, including the preamyloid protein aggregates immobilized on a solid support with labeled antibodies in suitable containers, along with any other reagents (e.g., wash solutions, enzyme substrate, anti-amyloid antibodies) or other materials required for the conduct of the assay.
- the reagents are usually premeasured for ease of use.
- An optional component of the kit is a set of instructions describing any of the available immunoassay methods.
- a kit for a direct assay can comprise preamyloid proteins aggregates immobilized on a solid immunoassay support and a container comprising labeled antibody to the amyloid protein, as well as the other reagents mentioned above.
- the following examples describe the expression vectors containing the 42 amino acid plaque core region (A42), and the 42 amino acid plaque core region including the 57 amino acid adjacent carboxy-terminal region of the beta-amyloid precursor protein (A99).
- Alternative constructs for the A42 and A99 constructs were prepared which included a 17 amino acid amyloid signal sequence. As these constructs did not express the amyloid protein well, further experimentation with these vectors was not performed.
- FIG. 1 il ⁇ lustrates the various amyloid expression constructs, all of which were modified at the 5' end to satisfy the clon ⁇ ing constraints of the vaccinia Pll promoter in the pUVl vector. Specifics for each construct are as follows:
- the A42-encoding sequence (nucleotides 2080 to 2205, numbered in accordance with the 751 amyloid pre- cursor sequence) was synthesized as a 145 basepair (bp) EcoRI-BamHI oligomer, provided below, containing the ap ⁇ intestinalte TGA stop codon and an amino-terminal Asn-Ser adaptor sequence:
- the synthetic fragment was ligated to EcoRI- and BamHI-digested pGeml (Promega-Biotec) , deriving pGemA42.
- the EcoRI-BamHI fragment of pGemA42 was subsequently isolated and ligated into the EcoRI-BamHI site of pUVl deriving pUVl:A42.
- the 590 bp Ddel-PvuII fragment of plasmid 4T4B was isolated from the carboxy-terminal 1 kilobase (kb) EcoRI fragment of 4T4B and ligated with a 27 bp EcoRI-Ddel adaptor sequence and cloned into the EcoRI- and Smal- digested pUVl, deriving pUVl:A99.
- the 761 bp Xbal-Sall fragment of pUVl:A99 was further subcloned into the Xbal-Sall vector fragment of mpl8 and pGem2. Sequence data confirmed the predicted sequence.
- the vaccinia insertion vectors described in Example 1 were used to generate amyloid-vaccinia re- combinant viruses as follows.
- Confluent monolayers of CV-1 cells in 60 mm dishes were infected with vaccinia virus (Wyeth strain) at a multiplicity of infection (moi) of 0.05 pfu/cell.
- vaccinia virus Wild-type vaccinia virus DNA
- m multiplicity of infection
- the cells were transfected with a calcium phosphate precipitate of 10 ug insertion plasmid DNA and 0.5 ug wild-type vaccinia virus DNA.
- Cells were fed with complete medium and incubated at 37°C for two days.
- Monolayers were collected and TK- vaccinia viruses were selected on TK-143 cells in the presence of 5- bromodeoxyuridine (BudR) at 25 ug/ l.
- BudR 5- bromodeoxyuridine
- the beta-amyloid antibodies were generated from synthetic peptides.
- the synthetic peptides were prepared using solid phase synthesis according to standard protocols. Purification of the crude peptides was ac ⁇ complished by desalting with gel filtration followed by ion-exchange chromatography and preparative reverse-phase liquid chromatography. Each peptide was fully character ⁇ ized by amino acid composition and sequence analysis. COOH-CORE corresponds to amino acids 653-
- C00H-B2 and C00H-C2 correspond to amino acids 736-751(NGYENPTYKFFEQMQN)
- C00H-B3 and C00H-C3 correspond to amino acids 705-719(KKKQYTSIHHGWEV)
- C00H-C5 corresponds to amino acids 729- 742(HLSKMQQNGYENPT) .
- Antibody titers against the appropriate peptide were determined by enzyme-linked immunosorbent assays coupled with horseradish peroxidase and found to be 7.4xl0 4 , 2.7xl0 5 , IxlO 5 , 9.1xl0 6 , 8.2xl0 5 , and 2.5xl0 5 for COOH-CORE, C00H-B2, C00H-C2, C00H-B3, C00H-C3, and C00H- C5, respectively.
- Antibodies to 9523 correspond to amino acids 673-685(AEDVGSKNGAIIG) and 9524 correspond to amino acids 701-712(LVMLKKKQYTSI) .
- Antibodies to these two peptides were generated by coinjecting New Zealand white rabbits each with 200 ug methylated bovine serum albumin (PBS) plus 200 ug of the respective synthetic peptide in PBS. Rabbits were boosted one, two and three weeks following primary inoculation with identical amounts of peptide.
- PBS methylated bovine serum albumin
- CV-1 cells were infected with W:99 at a multiplicity of infection of one.
- 35S-methionine 250 uCi/ml was added at 20 hr post infection for 4 hr.
- the expression product of W:A99 demonstrated high level expression of the 99 amino acid core protein and showed evidence of self-aggregation as well as ag ⁇ gregation with other proteins or self-aggregation combined with proteolysis since multi ers of A99 did not always occur in integers of 11.5-17 kd.
- SK-N-MC ATCC # HTB10
- IMR-32 ATCC # CCL127
- the culture medium for each host was as follows:
- CV-1 The medium was Eagle MEM supplemented with 10% FBS, penicillin, streptomycin and L- Gin-
- SK-N-MC Eagle MEM supplemented with 10% FBS, non- essential amino acids, penicillin, streptomycin and L-Gln.
- PC-12 DMEM21, 5% DHS, 5% DFBS and L-Gln;
- IMR-32 Eagle MEM (Hank's BSS) and 10% deltaFBS plus nonessential amino acids, penicillin, streptomycin and L-Gln.
- Each cell line was grown to confluency on a microscope slide divided into 4 individual chambers (Lab Tech) .
- One chamber was mock infected, the second infected with a control recombinant virus lacking A4 sequences
- FIG. 3 shows fluorescent photomicrographs of CV-
- a number of constructs expressing the beta- amyloid core protein were constructed using a derivative of the beta-actin expression/selection vector designated pHbetaAPr-1-neo.
- This vector illustrated in FIG. 4, is a combination of the following elements: a) bp 1-4300 is the 4.3 kb EcoRI-AluI fragment from the human beta-actin gene isolate pl4Tbeta-17 (Leavitt et al. , (1984) Mol Cell Biol 4:1961-1969). For sequencing details of the promoter see Ng et al. , (1985) Mol Cell Biol 5:2720-2732. The cap site, 5' untranslated region and IVS 1 positions are indicated in FIG. 4.
- bp 4300-4320 is in part derived from pSP64 polylinker (Melton et al., (1984) Nuc Acids Res 12:7035- 7056); c) bp 4320-6600 is derived from pcDVl (Okayama & Berg, (1983) Mol Cell Biol 3:280-289); and d) bp 6600-10000 is the PvuII-EcoRI fragment from pSV-neo (Southern & Berg, (1982) J Mol App Genet 1:327-341) containing the bacterial neo ycin gene linked to the SV40 origin plus early promoter.
- Beta-actin A42 was constructed by excising the EcoRI-BamHI 145 bp fragment from pGEM-A42, adding a Sall- EcoRI adaptor sequence (5'-TCG ACA TGG ATG CAC AAT TA-3') and cloning into the pAX-neo expression vector at the Sall-and BamHI sites.
- the beta-actin A99 plasmid was constructed by excising the 670 bp EcoRI-Hindlll fragment of pGEM_-A99, adding the above-described Sall-EcoRI adap ⁇ tor sequence and cloning into the pAX-neo vector at the Sail and HindiII sites.
- Each construct was introduced into CHO cells by the calcium phosphate precipitation method using 7 ug of each DNA per 10 cells, and a resistant population was selected with G418-neomycin. The efficiency of
- transfection for the A99 or A42 constructs was over 10 for 10 cells and pools of cells transfected with either beta-actin A99 or with beta-actin A42 were selected using G418-neomycin resistance (500 ug/ml).
- Cells infected with W:99 or W:42 which are capable of forming amyloid deposits are plated in a 96- well microtiter plate.
- an automated pipetter is used to introduce the drug to be tested to the cells.
- a range of concentrations of the drug is incubated in a tissue culture incubator (or preincubated) with the cells at 37 C for a predetermined time period, or alternatively, for 3 to 72 hours.
- the culture media is removed, and the cells are prepared for preamyloid measurement as follows.
- the cells are fixed for immunocytochemical staining with amyloid antibodies.
- the primary antibodies are introduced followed by incubation with labeled, secondary anti-antibodies and the level of binding between the primary and secondary antibodies is measured using an ELISA plate reader to record the optical density of the labeled antibody.
- a smaller optical density reading as compared to a control sample of cells grown in the absence of the test drug is indicative of that drug's ability to inhibit amyloid deposition.
- This procedure may be modified to permit detection of preamyloid dissolution using a correlative enzyme marker.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40876789A | 1989-09-18 | 1989-09-18 | |
US408767 | 1989-09-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0493470A1 true EP0493470A1 (fr) | 1992-07-08 |
EP0493470A4 EP0493470A4 (en) | 1992-11-25 |
Family
ID=23617679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19900914284 Ceased EP0493470A4 (en) | 1989-09-18 | 1990-09-12 | Assays and reagents for amyloid deposition |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0493470A4 (fr) |
JP (1) | JPH05502368A (fr) |
AU (1) | AU641434B2 (fr) |
CA (1) | CA2065404C (fr) |
WO (1) | WO1991004339A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06511387A (ja) * | 1991-12-24 | 1994-12-22 | アイシス・ファーマシューティカルス・インコーポレーテッド | β−アミロイド調節のための組成物および方法 |
US6610493B1 (en) * | 1993-06-17 | 2003-08-26 | Brigham And Women's Hospital | Screening compounds for the ability to alter the production of amyloid-β peptide |
US5804560A (en) * | 1995-01-06 | 1998-09-08 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
US5863902A (en) * | 1995-01-06 | 1999-01-26 | Sibia Neurosciences, Inc. | Methods of treating neurodegenerative disorders using protease inhibitors |
US7799535B1 (en) * | 1997-12-09 | 2010-09-21 | Arch Development Corporation | Methods for identifying factors that control the folding of amyloid proteins of diverse origin |
JP4344138B2 (ja) * | 2001-02-15 | 2009-10-14 | ユニバーシティ オブ シカゴ | タンパク質の折り畳みに影響する薬剤の酵母スクリーニング |
EP1793001B1 (fr) * | 2001-02-15 | 2011-11-09 | The University of Chicago | Cribles à base de levure pour agents affectant le repliement de protéines |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0274826A1 (fr) * | 1986-11-17 | 1988-07-20 | California Biotechnology, Inc. | Protéine recombinante amyloide d'alzheimer |
WO1989006242A1 (fr) * | 1987-10-08 | 1989-07-13 | The Mclean Hospital Corporation | Anticorps agissant sur un peptide de l'amyloide de sequence a4 |
WO1989006693A1 (fr) * | 1988-01-13 | 1989-07-27 | The Mclean Hospital Corporation | Sequences genetiques codant pour l'amyloide cerebrale d'alzheimer |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2403557A1 (fr) * | 1977-09-19 | 1979-04-13 | Beljanski Mirko | Procede et reactifs de detection des substances cancerigenes et des substances anticancereuses |
US4666829A (en) * | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
US4919915A (en) * | 1987-03-03 | 1990-04-24 | Paul Averback | Method for detecting the ability to prevent red-to-green congophilic birefringence |
US4912206A (en) * | 1987-02-26 | 1990-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | CDNA clone encoding brain amyloid of alzheimer's disease |
CA1340802C (fr) * | 1987-08-15 | 1999-10-26 | Yasuyuki Takahashi | Proteine precurseur de l'amyloide senile et anticorps specifique pour cette proteine |
WO1989007657A1 (fr) * | 1988-02-10 | 1989-08-24 | The Children's Medical Center Corporation | Precurseurs de proteines amyloides, sondes genetiques, anticorps, et modes d'utilisation |
-
1990
- 1990-09-12 AU AU64311/90A patent/AU641434B2/en not_active Expired
- 1990-09-12 WO PCT/US1990/005155 patent/WO1991004339A1/fr not_active Application Discontinuation
- 1990-09-12 JP JP2513439A patent/JPH05502368A/ja active Pending
- 1990-09-12 CA CA002065404A patent/CA2065404C/fr not_active Expired - Lifetime
- 1990-09-12 EP EP19900914284 patent/EP0493470A4/en not_active Ceased
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0274826A1 (fr) * | 1986-11-17 | 1988-07-20 | California Biotechnology, Inc. | Protéine recombinante amyloide d'alzheimer |
WO1989006242A1 (fr) * | 1987-10-08 | 1989-07-13 | The Mclean Hospital Corporation | Anticorps agissant sur un peptide de l'amyloide de sequence a4 |
WO1989006693A1 (fr) * | 1988-01-13 | 1989-07-27 | The Mclean Hospital Corporation | Sequences genetiques codant pour l'amyloide cerebrale d'alzheimer |
Non-Patent Citations (1)
Title |
---|
See also references of WO9104339A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2065404A1 (fr) | 1991-03-19 |
AU641434B2 (en) | 1993-09-23 |
WO1991004339A1 (fr) | 1991-04-04 |
AU6431190A (en) | 1991-04-18 |
CA2065404C (fr) | 2002-12-24 |
JPH05502368A (ja) | 1993-04-28 |
EP0493470A4 (en) | 1992-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5221607A (en) | Assays and reagents for amyloid deposition | |
Otvos Jr et al. | Monoclonal antibody PHF‐1 recognizes tau protein phosphorylated at serine residues 396 and 404 | |
US6610493B1 (en) | Screening compounds for the ability to alter the production of amyloid-β peptide | |
CA2205359C (fr) | Methode d'assistance au diagnostic de la maladie d'alzheimer par mesure du peptide amyloide-beta (x->=41) et de la proteine tau | |
CA2174632C (fr) | Procede de detection d'inhibiteurs de la production de peptides beta-amyloides | |
CA2118243C (fr) | Methodes et compositions pour surveiller le traitement par les cellules de la proteine precurseur .beta.-amyloide | |
Selkoe et al. | Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer's disease | |
US5593846A (en) | Methods for the detection of soluble β-amyloid peptide | |
US7674599B2 (en) | Methods of using antibodies to detect alpha-synuclein in fluid samples | |
US5837672A (en) | Methods and compositions for the detection of soluble β-amyloid peptide | |
US5733734A (en) | Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments | |
US7479372B2 (en) | Beta-secretase substrates and uses thereof | |
WO1997048983A9 (fr) | CRIBLAGE DE COMPOSES CAPABLES DE MODIFIER LA PRODUCTION DE PEPTIDE AMYLOIDE-β (x-≥41) | |
AU641434B2 (en) | Assays and reagents for amyloid deposition | |
WO1994013315A1 (fr) | Nouvelle proteine eucaryote de transcription appelee facteur de cellules hotes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19920317 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19921005 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE |
|
17Q | First examination report despatched |
Effective date: 19940520 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SCIOS NOVA INC. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 19960311 |